Clinical trials: Melanoma (Skin), open to volunteers
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Skin Cancer Prevention, Melanoma In Situ
Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care
The project is a national, prospective, multicenter, single-arm interventional pilot of screening skin tumors in the Czech Republic.
- Conditions
- Skin Cancer Prevention, Melanoma In Situ, Skin Lesions, Skin Cancer
- Trial name
- MEL (NCT07349940)
- Testing
- Intervention with telemedicine tool
- Where
- 5 sites in Czechia
- Volunteers
- 1,440 people
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
Non Small Cell Lung Cancer, Melanoma (Skin Cancer)
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
This study aims to investigate the role of the gut microbiota and its derived factors, including bacterial-associated antigens that mimic tumor-associated antigens, in predicting response to immune checkpoint inhibitor…
- Conditions
- Non Small Cell Lung Cancer, Melanoma (Skin Cancer), Endometrial Cancer, Cervical Cancer
- Trial name
- CERBERO (NCT07815873)
- Testing
- sample collection
- Where
- Italy
- Volunteers
- 360 people
- Sponsor
- European Institute of Oncology
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 14 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Melanoma, Dysplastic Nevus Syndrome
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions.
- Trial name
- NCT00040352
- Where
- 2 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis.
- Conditions
- Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia
- Trial name
- NCT07072728
- Testing
- Psilocybin therapy
- Where
- 5 sites in Australia
- Volunteers
- 87 people
- Sponsor
- Psyence Australia Pty Ltd
Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin
TruScore Standalone Clinical Study
The goal of this clinical trial is to evaluate if the TruScore device can accurately diagnose suspicious skin lesions in patients aged 22 years and older.
- Conditions
- Melanoma and Other Malignant Neoplasms of Skin, Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma of the Skin
- Trial name
- Standalone (NCT06793423)
- Testing
- Skin lesion diagnostic device evaluation
- Where
- 6 sites in United States
- Volunteers
- 464 people
- Sponsor
- VeriSkin, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
The objective of this prospective multicenter study is to evaluate whether the analysis of immunological biomarkers present in circulating extracellular vesicles is associated with the response to anti-PD-1/PD-L1 treatments in…
- Trial name
- EVpredict (NCT07376512)
- Where
- 5 sites in France
- Volunteers
- 378 people
- Sponsor
- Centre Georges Francois Leclerc
HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
This Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor…
- Conditions
- HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer
- Trial name
- NCT07808164
- Testing
- IHC analysis for ENPP1, cGAS, and FAP expression
- Where
- 2 sites in Vietnam
- Volunteers
- 162 people
- Sponsor
- Tam Anh Research Institute
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors.
- Trial name
- NCT07287917
- Testing
- AMXT 1501 Dicaprate, DFMO, Fulvestrant
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Aminex Therapeutics, Inc.
Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin
Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
The purpose of this study is to learn whether a computer-based support tool called DEXI (Dermoscopy EXplainable Intelligence) can help dermatologists decide whether a lesion may be melanoma, a serious type of skin cancer.
- Conditions
- Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin, Melanoma in Situ, Carcinoma in Situ of Skin
- Trial name
- NCT07890415
- Testing
- Clinical decision support tool
- Where
- 8 sites in United States
- Volunteers
- 14,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative
Intratumoral N17350 in Advanced Solid Tumors
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
- Trial name
- OP-NEU-101 (NCT07339176)
- Testing
- N17350
- Where
- 9 sites in United States, Australia
- Volunteers
- 275 people
- Sponsor
- Onchilles Pharma Inc
Skin Cancer
Implementation of Teledermoscopy and Artificial Intelligence
The study has 2 parts. Part 1 will investigate the effects of introducing teledermoscopy in clinical practice, more specifically the change in referral patterns, the risk of undetected skin cancers and the effect on diagnostic…
- Trial name
- NCT05033678
- Testing
- Diagnostic algorithms
- Where
- Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Region Skane
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT05896839
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma (Skin), Metastatic Melanoma
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in…
- Conditions
- Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
- Trial name
- NCT05655312
- Testing
- [203Pb]VMT01, [212Pb]VMT01, Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Non-melanoma Skin Cancer, Carcinoma, Squamous Cell
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection.
- Conditions
- Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell, Keratinocyte Carcinoma
- Trial name
- SPRINTR (NCT05955924)
- Testing
- Nicotinamide
- Where
- 7 sites in Canada
- Volunteers
- 396 people
- Sponsor
- Women's College Hospital
Breast Cancer, Ovarian Cancer
Dermatological Effects and Quality of Life in Oncology Patients
This is a monocentric, low-risk interventional study designed to characterize established treatment-related dermatologic toxicity in patients receiving systemic anticancer therapies.
- Conditions
- Breast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer)
- Trial name
- ReGenera (NCT07869186)
- Testing
- skin barrier assessment
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- European Institute of Oncology
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca